Tumor Infiltrating Lymphocytes: A New Frontier in Cancer Immunotherapy
REPORT INCLUDES:
- An overview of Tumor Infiltrating Lymphocytes (TILs) for the treatment of metastatic cancer
- Discussion of the development of TIL as a treatment option for melanoma and the possibilities to expand this therapy to other types of cancer
- Exploration of adoptive T-cell therapy (ATCT) using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma, and the curative potential of ATCT in a variety of other solid tumors
- Comparison between two main technologies of tumor immunotherapy, chimeric antibody receptor engineered T Cell (CAR-T) and genetically modified T cell receptors (TCR)
- Information on the role of TILs as a strong prognostic biomarker for triple-negative breast cancer (TNBC) and their potential ramifications
CHAPTER 1 THE EMERGENCE OF CELL THERAPY USING TILS
Introduction
Analyst's Credentials
Related Reports
CHAPTER 2 DEVELOPMENT OF TIL THERAPIES IN METASTIC MELANOMA
TIL Generation Explained
Importance of Lymphodepletion
Role of Interleukin-2
Feasibility of TIL as a Mainstream Treatment Option
CHAPTER 3 DEVELOPMENT OF TIL THERAPIES IN OTHER TUMOUR TYPES
Cervical Cancer
Ovarian Cancer
Kidney Cancer
Gastrointestinal Cancer
Head and Neck Cancers
CHAPTER 4 CLINICAL DEVELOPMENT OF TIL THERAPIES
Lifileucel (LN-144), Iovance Biotherapeutics
LN-145, Iovance Biotherapeutics
TILT-123, TILT Biotherapeutics
Optera Therapeutics Corp.
Other Centers Conducting TIL Research
Future Perspectives for TIL
CHAPTER 5 REFERENCES
Introduction
Analyst's Credentials
Related Reports
CHAPTER 2 DEVELOPMENT OF TIL THERAPIES IN METASTIC MELANOMA
TIL Generation Explained
Importance of Lymphodepletion
Role of Interleukin-2
Feasibility of TIL as a Mainstream Treatment Option
CHAPTER 3 DEVELOPMENT OF TIL THERAPIES IN OTHER TUMOUR TYPES
Cervical Cancer
Ovarian Cancer
Kidney Cancer
Gastrointestinal Cancer
Head and Neck Cancers
CHAPTER 4 CLINICAL DEVELOPMENT OF TIL THERAPIES
Lifileucel (LN-144), Iovance Biotherapeutics
LN-145, Iovance Biotherapeutics
TILT-123, TILT Biotherapeutics
Optera Therapeutics Corp.
Other Centers Conducting TIL Research
Future Perspectives for TIL
CHAPTER 5 REFERENCES
LIST OF TABLES
Table 1: TILs and Tumor Specific Antigens
Table 2: Adoptive T-Cell Therapy (ATC) Cellular Therapies
Table 3: Clinical Trials Studying TIL Therapies
Table 1: TILs and Tumor Specific Antigens
Table 2: Adoptive T-Cell Therapy (ATC) Cellular Therapies
Table 3: Clinical Trials Studying TIL Therapies
LIST OF FIGURES
Figure 1: Generation of Tumor Infiltrating Lymphocytes
Figure 2: IL-2 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types
Figure 3: TILT Biotherapeutics Development Pipeline
Figure 1: Generation of Tumor Infiltrating Lymphocytes
Figure 2: IL-2 Signaling Pathways and their Primary Biological Effects in Different Immune Cell Types
Figure 3: TILT Biotherapeutics Development Pipeline
